Form 4: Vaccinex Director Barbara Yanni Reports Stock Option Acquisition

Director Barbara Yanni reports the acquisition of stock options in Vaccinex, Inc.

Summary

• Barbara Yanni, a director of Vaccinex, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The report details the acquisition of 10,108 stock options at a price of $5.75 on May 10, 2024, exercisable until May 10, 2025.
• The options were granted pursuant to the Company's 2018 Omnibus Incentive Plan and expire on May 10, 2034, or five years following retirement or cessation of services, whichever occurs first.
• The filing also reflects the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally a positive sign, but the document itself is a routine regulatory filing.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a slight positive impact on shareholder sentiment.

Key Dates

Keywords

Vaccinex, VCNX, Form 4, Stock Options, Director, Beneficial Ownership, Reverse Stock Split, Barbara Yanni